Condition
Encephalopathy, Hypoxic-Ischemic
Total Trials
6
Recruiting
0
Active
1
Completed
3
Success Rate
75.0%-12% vs avg
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
16.7%
1 terminated out of 6 trials
Success Rate
75.0%
-11.5% vs benchmark
Late-Stage Pipeline
17%
1 trials in Phase 3/4
Results Transparency
133%
4 of 3 completed with results
Key Signals
4 with results75% success
Data Visualizations
Phase Distribution
6Total
Not Applicable (4)
P 1 (1)
P 3 (1)
Trial Status
Completed3
Active Not Recruiting1
Terminated1
Unknown1
Trial Success Rate
75.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT01192776Not ApplicableTerminated
Optimizing (Longer, Deeper) Cooling for Neonatal Hypoxic-Ischemic Encephalopathy(HIE)
NCT06370624Not ApplicableActive Not RecruitingPrimary
PEDI-REAVASC Resonance Imaging of Infants With Hypoxic Ischemic Encephalopathy After Hypothermia Treatment.
NCT01793129Not ApplicableCompleted
Preemie Hypothermia for Neonatal Encephalopathy
NCT03162653Phase 3UnknownPrimary
Effect of Allopurinol for Hypoxic-ischemic Brain Injury on Neurocognitive Outcome
NCT00614744Not ApplicableCompleted
Late Hypothermia for Hypoxic-Ischemic Encephalopathy
NCT01862250Phase 1CompletedPrimary
Safety of Clonidine in Infants With Hypoxic Ischemic Encephalopathy During Therapeutic Hypothermia
Showing all 6 trials